MetaCap

Nanobiotix S.A. (NBTX) vs Rapport Therapeutics (RAPP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nanobiotix S.A. (NBTX) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 26.6% versus a loss of 15.0%. Rapport Therapeutics is the larger company by market cap ($1.37 billion vs $1.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBTX+26.61%RAPP-15.01%
+172%+73%-26%
Nov 21, 20251 yearNov 20, 2026
NBTX+364.91%RAPP+11.35%
+847%+372%-103%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBTX versus RAPP key metrics
MetricNBTXRAPP
Share price$26.50$23.16
Market cap$1.35B$1.37B
1-day change-2.98%-1.82%
YTD return+14.62%-23.67%
1-year return+26.61%-15.01%
5-year return+213.98%—
EPS (TTM)$-1.27$-3.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-111.48M
52-week high$57.14$52.93
52-week low$19.14$22.06
Distance from 52-week high-53.62%-56.24%
Analyst consensusnonestrong_buy
Avg. price target upside+101.06%+177.25%
Average volume148.94K790.62K
Shares outstanding50.95M59.28M
Employees9884
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NBTX has outperformed RAPP by 41.6 percentage points over the past year.

About Nanobiotix S.A.

NBTX stock →

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

NBTX vs RAPP FAQ

Which is bigger, Nanobiotix S.A. or Rapport Therapeutics?

Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.37B compared with $1.35B for Nanobiotix S.A. (NBTX).

Which stock has performed better over the past year, NBTX or RAPP?

NBTX returned +26.61% over the past 12 months, compared with -15.01% for RAPP (price return, excluding dividends). Past performance does not predict future results.

Are Nanobiotix S.A. and Rapport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons